Company / Shareholders' Equity
ARDELYX, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$166.9M
FY2025
5-year range
$82.6M / $173.3M
FY2021-FY2025
Trend
-3.7%
vs FY2024
Sector context
#161 of 213
Health Care
What the data says
ARDELYX, INC.'s shareholders' equity of $167M is lower than 76% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from $61M in FY2016 to $187M in FY2019.
Based on SEC 10-K filings.
$167M in FY2025 with a 5-year CAGR of +5.8%.
Remained stable around $167M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- +5.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 213This company $166.9M Sector average $2.5B
▼
-93.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 3.7% year-over-year.
- Ranks #161 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $166.9M | -3.7% |
| FY2024 | $173.3M | +3.9% |
| FY2023 | $166.8M | +69.7% |
| FY2022 | $98.3M | +19.0% |
| FY2021 | $82.6M | -34.5% |
| FY2020 | $126.1M | -32.4% |
| FY2019 | $186.7M | +61.2% |
| FY2018 | $115.8M | +6.3% |
| FY2017 | $108.9M | +79.5% |
| FY2016 | $60.7M | -44.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026